Aileron Therapeutics, Inc. (NASDAQ:ALRN) Short Interest Down 13.4% in September

Aileron Therapeutics, Inc. (NASDAQ:ALRN) was the recipient of a large drop in short interest during the month of September. As of September 15th, there was short interest totalling 257,100 shares, a drop of 13.4% from the August 31st total of 296,800 shares. Currently, 1.3% of the shares of the company are sold short. Based on an average daily trading volume, of 82,900 shares, the days-to-cover ratio is currently 3.1 days.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. Texas Capital Bank Wealth Management Services Inc lifted its position in shares of Aileron Therapeutics by 65.9% in the first quarter. Texas Capital Bank Wealth Management Services Inc now owns 26,171 shares of the company’s stock valued at $174,000 after buying an additional 10,398 shares during the last quarter. University of Texas Texas AM Investment Management Co. acquired a new stake in shares of Aileron Therapeutics during the 2nd quarter valued at $4,925,000. Warberg Asset Management LLC acquired a new stake in shares of Aileron Therapeutics during the 2nd quarter valued at $86,000. Finally, Nantahala Capital Management LLC lifted its holdings in Aileron Therapeutics by 82.1% during the 2nd quarter. Nantahala Capital Management LLC now owns 464,367 shares of the company’s stock worth $1,286,000 after buying an additional 209,367 shares during the period. 90.89% of the stock is currently owned by institutional investors.

Aileron Therapeutics Trading Up 1.7 %

Shares of NASDAQ:ALRN opened at $3.65 on Monday. Aileron Therapeutics has a 1-year low of $1.01 and a 1-year high of $7.42. The firm has a market capitalization of $78.89 million, a PE ratio of -1.14 and a beta of 2.33. The business’s 50 day moving average is $2.57 and its 200-day moving average is $3.59.

Aileron Therapeutics (NASDAQ:ALRN) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.20). On average, sell-side analysts predict that Aileron Therapeutics will post -1.41 EPS for the current year.

Aileron Therapeutics Company Profile

Aileron Therapeutics, Inc, a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).